CHIME requests more time in its MU Stage 2 comments

Time, Deadline - 26.64 Kb
The College of Healthcare Information Management Executives (CHIME) has submitted its comments on the proposed rules for Stage 2 meaningful use, calling for more time to allow healthcare organizations to better prepare.

Comments filed with both the Centers for Medicare & Medicaid Services (CMS) and Office of the National Coordinator for Health IT (ONC) identified concerns related to the proposed Stage 2 EHR reporting period as well as CMS’ varying approach to clinical quality measures (CQMs). CHIME also made recommendations on all 42 proposed objectives for eligible professionals (EPs), eligible hospitals (EHs) and critical access hospitals (CAHs).

CHIME recommended that CMS allow all three groups to demonstrate meaningful use during a continuous 90-day EHR reporting period for their first payment year in Stage 2, mimicking the approach used in Stage 1.

“To allow adequate time for application development, provider adoption and testing, CMS should follow the precedent set in Stage 1,” CHIME said. “And similar to Stage 1, the EHR reporting period would be any continuous 90-day period within the first payment year of Stage 2 and a 365-day reporting period for all subsequent payment years within Stage 2.”

“We felt the approach taken in Stage 1 gave providers much-needed time to make sure the correct fields were populating and accurate meaningful use reports were being produced–we think a similar approach is needed for Stage 2 and beyond,” said Pam McNutt, senior vice president and chief information officer at Dallas-based Methodist Health System.

“While we appreciate the delay of Stage 2 to fiscal year 2014, that decision was necessary, given that no one would be in a position to meet Stage 2 requirements beginning Oct. 1, 2012,” said McNutt, a member of CHIME’s Policy Steering Committee. “By giving providers flexibility through a 90-day reporting window, CMS can ensure that more Stage 1 meaningful users will become Stage 2 meaningful users.”

In both letters, to CMS and ONC, CHIME commented on the challenges involved with clinical quality measures. “The accurate reporting of quality measures is one of the most daunting challenges faced by providers today,” CHIME said. “Through our experiences with Stage 1, we found that although EHR products were able to automatically produce CQM reports, the data was inaccurate and largely incomparable across different providers.”

As part of base EHR certification, CHIME urged ONC to require certification of EHR products to all CQMs needed to meet meaningful use in each setting. CHIME wrote that “certification should include all CQMs for associated settings. And in order to minimize the costs of development and implementation, we recommend that ONC work with CMS to limit the total number of CQMs associated with each setting.”

“Quality measures are a vital component to increasing care efficiency, decreasing disparities and lowering costs,” said Elizabeth O. Johnson, vice president of applied clinical informatics at Tenet Healthcare, and a member of CHIME’s Policy Steering Committee. “It is clear that ONC recognizes the value of quality measures, but the state of quality measurement needs to mature. HHS has been working to harmonize CQMs across its various reporting programs; however, more must be done to make the quality metrics consistent and meaningful.”

CHIME’s comments include suggestions on all 42 objectives and measures for both ambulatory and inpatient settings of care.

While CHIME supported nearly every measure meant to meet each objective, member CIOs were concerned with the lack and types of menu options for EPs, EHs and CAHs. “The menu set for both EPs and hospitals is quite small in relation to the minimum number that would need to be met, thereby providing relatively few options for EPs and hospitals,” the letter said. “A number of the proposed menu set objectives and measures also would have non-trivial cost implications for EPs and hospitals.” CHIME urged CMS to carefully assess both the number and feasibility of menu options for the average physician practice or the average hospital in finalizing its rule for Stage 2.

CHIME’s comments to CMS can be found here. For CHIME’s letter to ONC, click here.
Beth Walsh,

Editor

Editor Beth earned a bachelor’s degree in journalism and master’s in health communication. She has worked in hospital, academic and publishing settings over the past 20 years. Beth joined TriMed in 2005, as editor of CMIO and Clinical Innovation + Technology. When not covering all things related to health IT, she spends time with her husband and three children.

Around the web

The tirzepatide shortage that first began in 2022 has been resolved. Drug companies distributing compounded versions of the popular drug now have two to three more months to distribute their remaining supply.

The 24 members of the House Task Force on AI—12 reps from each party—have posted a 253-page report detailing their bipartisan vision for encouraging innovation while minimizing risks. 

Merck sent Hansoh Pharma, a Chinese biopharmaceutical company, an upfront payment of $112 million to license a new investigational GLP-1 receptor agonist. There could be many more payments to come if certain milestones are met.